Expression of MDR1 in epithelial ovarian cancer and its association with disease progression

Oncology Research

Volumn 16, Issue 8, 2007, Pages 395-403

  Lu, Lingeng ^a   Katsaros, Dionyssios ^b   Wiley, Andrew ^a   Rigault De La Longrais, Irene A ^b   Puopolo, Manuela ^b   Yu, Herbert ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

MDR1; Ovarian cancer; Prognosis

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR ALPHA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P16; SOMATOMEDIN B; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

EID: 34548694725     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783980892     Document Type: Article

References (37)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics, 2006. CA Cancer J. Clin. 56:106-130; 2006.
2. Neijt, J. P.; ten Bokkel Huinink, W. W.; van der Burg, M. E.; van Oosterom, A. T.; Willemse, P. H.; Vermorken, J. B.; van Linden, A. C.; Heintz, A. P.; Aartsen, E.; van Lent, M.; et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur. J. Cancer 27:1367-1372; 1991.
3. McGuire, W. P.; Hoskins, W. J.; Brady, M. F.; Kucera, P. R.; Partridge, E. E.; Look, K. Y.; Clarke-Pearson, D. L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1-6; 1996.
4. Markman, M.; Rothman, R.; Hakes, T.; Reichman, B.; Hoskins, W.; Rubin, S.; Jones, W.; Almadrones, L.; Lewis, Jr., J. L. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9:389-393; 1991.
5. Arts, H. J.; Katsaros, D.; de Vries, E. G.; Massobrio, M.; Genta, F.; Danese, S.; Arisio, R.; Scheper, R. J.; Kool, M.; Scheffer, G. L.; Willemse, P. H.; van der Zee, A. G.; Suurmeijer, A. J. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 5:2798-2805; 1999.
6. Germann, U. A. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer 32A:927-944; 1996.
7. Bosch, I.; Croop, J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta 1288:F37-54; 1996.
8. Jonker, J. W.; Buitelaar, M.; Wagenaar, E.; Van Der Valk, M. A.; Scheffer, G. L.; Scheper, R. J.; Plosch, T.; Kuipers, F.; Elferink, R. P.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA 99:15649-15654; 2002.
9. van Herwaarden, A. E.; Jonker, J. W.; Wagenaar, E.; Brinkhuis, R. F.; Schellens, J. H.; Beijnen, J. H.; Schinkel, A. H. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63:6447-6452; 2003.
10. Hadnagy, A.; Gaboury, L.; Beaulieu, R.; Balicki, D. SP analysis may be used to identify cancer stem cell populations. Exp. Cell Res. 312:3701-3710; 2006.
11. Zhang, W.; Ling, V. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J. Cell Physiol. 184:17-26; 2000.
12. Xing, H.; Wang, S.; Hu, K.; Tao, W.; Li, J.; Gao, Q.; Yang, X.; Weng, D.; Lu, Y.; Ma, D. Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J. Cancer Res. Clin. Oncol. 131:511-519; 2005.
13. Kuo, M. T.; Julian, J.; Husain, F.; Song, R.; Carson, D. D. Regulation of multidrug resistance gene mdr1b/mdr1 expression in isolated mouse uterine epithelial cells. J. Cell Physiol. 164:132-141; 1995.
14. Materna, V.; Pleger, J.; Hoffmann, U.; Lage, H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: Correlation with chemotherapeutic response. Gynecol. Oncol. 94:152-160; 2004.
15. Penson, R. T.; Oliva, E.; Skates, S. J.; Glyptis, T.; Fuller, Jr., A. F.; Goodman, A.; Seiden, M. V. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol. Oncol. 93:98-106; 2004.
16. Yokoyama, Y.; Sato, S.; Fukushi, Y.; Sakamoto, T.; Futagami, M.; Saito, Y. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J. Obstet. Gynaecol. Res. 25:387-394; 1999.
17. Ozalp, S. S.; Yalcin, O. T.; Tanir, M.; Kabukcuoglu, S.; Etiz, E. Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies. Eur. J. Gynaecol. Oncol. 23:337-340; 2002.
18. Lu, L.; Katsaros, D.; Wiley, A.; Rigault de la Longrais, I. A.; Risch, H. A.; Puopolo, M.; Yu, H. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin. Cancer Res. 12:1208-1214; 2006.
19. Katsaros, D.; Cho, W.; Singal, R.; Fracchioli, S.; Rigault De La Longrais, I. A.; Arisio, R.; Massobrio, M.; Smith, M.; Zheng, W.; Glass, J.; Yu, H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol. Oncol. 94:685-692; 2004.
20. Rustin, G. J.; Nelstrop, A. E.; Tuxen, M. K.; Lambert, H. E. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group Study. Ann. Oncol. 7:361-364; 1996.
21. FIGO. Changes in defintion of clinical staging for carcinoma of the cervix and ovary. Am. J. Obstet. Gynecol. 56:263-264; 1987.
22. Serov, S. F.; Soully, R. F.; Sobin, L. H. Histological typing of ovarian tumors. In: International histological classification of tumors. Geneva: WHO; 1973:37-42.
23. Ohishi, Y.; Oda, Y.; Uchiumi, T.; Kobayashi, H.; Hirakawa, T.; Miyamoto, S.; Kinukawa, N.; Nakano, H.; Kuwano, M.; Tsuneyoshi, M. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 8:3767-3775; 2002.
24. Joncourt, F.; Buser, K.; Altermatt, H.; Bacchi, M.; Oberli, A.; Cerny, T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol. Oncol. 70:176-182; 1998.
25. Noonan, K. E.; Beck, C.; Holzmayer, T. A.; Chin, J. E.; Wunder, J. S.; Andrulis, I. L.; Gazdar, A. F.; Willman, C. L.; Griffith, B.; Von Hoff, D. D.; et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87:7160-7164; 1990.
26. Holzmayer, T. A.; Hilsenbeck, S.; Von Hoff, D. D.; Roninson, I. B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst. 84:1486-1491; 1992.
27. Kavallaris, M.; Leary, J. A.; Barrett, J. A.; Friedlander, M. L. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett. 102:7-16; 1996.
28. van der Zee, A. G.; Hollema, H.; Suurmeijer, A. J.; Krans, M.; Sluiter, W. J.; Willemse, P. H.; Aalders, J. G.; de Vries, E. G. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13:70-78; 1995.
29. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci. 13:134-136; 1992.
30. Parekh, H.; Wiesen, K.; Simpkins, H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem. Pharmacol. 53:461-470; 1997.
31. Johnson, S. W.; Ozols, R. F.; Hamilton, T. C. Mechanisms of drug resistance in ovarian cancer. Cancer 71:644-649; 1993.
32. Baekelandt, M. M.; Holm, R.; Nesland, J. M.; Trope, C. G.; Kristensen, G. B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 20:1061-1067; 2000.
33. Lage, H. ABC-transporters: Implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents 22:188-199; 2003.
34. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: From genomics to mechanism. Oncogene 22:7468-7485; 2003.
35. Lincke, C. R.; van der Bliek, A. M.; Schuurhuis, G. J.; van der Velde-Koerts, T.; Smit, J. J.; Borst, P. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 50:1779-1785; 1990.
36. Minemura, M.; Tanimura, H.; Tabor, E. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int. J. Oncol. 15:559-563; 1999.
37. Hirose, M.; Kuroda, Y. p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines. Cancer Lett. 129:165-171; 1998.